PCT & Ancillaries Peptide Dosage Protocols
Post-cycle therapy and ancillary research compounds restore endogenous hormone production after androgenic protocols. Covers aromatase inhibitors (anastrozole, letrozole, exemestane), SERMs (tamoxifen, raloxifene, enclomiphene), and prolactin modulators (cabergoline, pramipexole).
3 protocols indexed
Gonadorelin
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), an endogenous decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced by hypothalamic neurons. Pulsatile GnRH release stimulates pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive gonadal steroidogenesis and gametogenesis. Gonadorelin has been FDA approved historically (Factrel injection, Lutrepulse pump) for evaluation of pituitary gonadotrope function and for induction of ovulation in hypothalamic amenorrhea, although original branded products have been withdrawn from the U.S. market. Diagnostic doses are 0.1 mg subcutaneously or intravenously; pulsatile therapy uses 5–20 mcg every 90–120 minutes via portable infusion pump. Off-label, gonadorelin is increasingly used at 50–200 mcg subcutaneously two to three times weekly as an adjunct in testosterone replacement therapy to preserve testicular volume and fertility, in place of hCG.
Open Protocolarrow_forwardResearch PeptideHCG
Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of an alpha subunit shared with LH, FSH, and TSH and a unique beta subunit. Produced by the syncytiotrophoblast during pregnancy, hCG acts as a luteinizing hormone receptor agonist on Leydig cells in the testes and theca/granulosa cells in the ovary, driving steroidogenesis and supporting the corpus luteum during early gestation. Recombinant and urinary-derived hCG are FDA approved for ovulation induction, prepubertal cryptorchidism, and hypogonadotropic hypogonadism. In post-cycle therapy and as an adjunct to testosterone replacement, hCG is used at 500–1500 IU subcutaneously two to three times weekly to restore endogenous testicular function suppressed by anabolic-androgenic steroids or exogenous testosterone. Typical PCT protocols use 1000–2000 IU every other day for two to three weeks before transitioning to selective estrogen receptor modulators. hCG is not approved for weight loss; the FDA has explicitly warned against this off-label use.
Open Protocolarrow_forwardResearch PeptideHMG
Human menopausal gonadotropin (hMG, menotropins) is a purified mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity extracted from the urine of postmenopausal women, typically in a 1:1 FSH:LH bioactivity ratio. Menopur (highly purified hMG) and similar branded products are FDA approved for controlled ovarian stimulation in women undergoing assisted reproductive technology (ART) and for induction of ovulation in anovulatory women. Standard fertility protocols initiate hMG at 75–225 IU subcutaneously daily, titrating up to 450 IU/day based on follicular response. In men with hypogonadotropic hypogonadism, hMG (75–150 IU subcutaneously three times weekly) is combined with hCG to drive spermatogenesis. In off-label male PCT applications, hMG is used at 75–150 IU two to three times weekly to support FSH-driven Sertoli cell recovery alongside hCG-driven Leydig cell stimulation, although controlled clinical evidence in this context is limited.
Open Protocolarrow_forward